Top Leading players in the industry have adopted product approval as their key strategy to enhance their product offerings by expanding the usage of transcatheter aortic valves for new indications, such as intermediate risk aortic stenosis patients. The key players profiled in this report include Abbott Laboratories, Boston Scientific Corporation (Symetis SA), Bracco S.p.A. (HLT, Inc.), Edwards Lifesciences Corporation, JenaValve Technology, Inc., JC Medical, Inc., Medtronic plc, Meril Life Sciences Pvt. Ltd., NVT AG, and Venus Medtech, Inc.
“After the U.S. and Europe, Japan holds the largest share for TAVI devices market. This is mainly due to large population of elderly above the age of 65 years with aortic stenosis, high adoption of TAVI devices for the treatment of aortic stenosis, and favorable reimbursement policies in the country. Furthermore, technological advancements in the field of TAVI devices is expected to further propel the market growth.”
Transcatheter Aortic Valve Transplantation (Tavi) Market revenue is estimated at $ 2,761 million in 2017 and is expected to grow at an average annual rate of 13.8% from 2018 to 2025, reaching $ 813 million by 2025. The mass market is estimated at 107,011 in 2017 and is expected to reach 337,778 units by 2025 and is expected to grow at an annual average of 14.8% from 2018 to 2025.
Download Report Sample @ https://www.alliedmarketresearch.com/request-sample/1675
Transatheter Aortic Valve Replacement (TAV) is a minimally invasive procedure performed to treat high-risk patients suffering from aortic stenosis. This high-risk patient refers to a group of patients who are unable to undergo surgery and undergo surgical aortic valve replacement (SAVR) procedures. Because open heart surgery is too dangerous, the elderly population (over 75 years old) belongs to the high risk group. TAVR involves the insertion of a percutaneous aortic valve to regenerate the circulatory capacity of the aortic valve. The need for aortic valve implantation is increasing due to increased aortic stenosis.
The TAVI market is in the growth phase and is largely driven by an increase in the prevalence of aortic stenosis and an increase in the elderly population. In addition, as adoption rates of percutaneous aortic transplants increase, new medical device approvals and improved medical infrastructure in developing countries are another factor driving market growth. However, the high cost of transcutaneous aortic valves and transplant procedures hamper the growth of the TAVI market due to the reimbursement of such devices and the lack of strict admission.
The report segments the TAVI market based on the approach used for implantation. Mainly, three types of approaches are used to implant the transcatheter aortic valve in patients-transfemoral, transapical, and transaortic implantation. Transfemoral implantation was the highest revenue-generating segment in the global market (in terms of value and volume) in 2017, as it does not require a chest incision. Furthermore, transaortic segment is projected to grow at the highest CAGR of 19.1% (in terms of value) and 20.1% (in terms of volume) by 2025, due to positive outcomes of several clinical trials.
Key Findings of the Transcatheter Aortic Valve Implantation (TAVI) Market:
- In 2017, transfemoral implantation generated the highest revenue, and is projected to grow at a CAGR of 13.2% (in terms of value) during the forecast period.
- Both in terms of value and volume, the Europe TAVI market is expected to maintain its leading position during the forecast period.
- Asia-Pacific is expected to be the fastest growing region, and is expected to grow with a CAGR of 18.6% (in terms of value) from 2018 to 2025.
- Germany was the leading country whereas the UK is projected to be the fastest growing country in the Europe TAVI market.
- India is the fastest growing country in the Asia-Pacific TAVI market and is expected to grow at a CAGR of 29.8% (in terms of revenue) from 2018 to 2025.
Europe accounted for a major share in the global TAVI market (in terms of value and volume) in 2017, and is expected to maintain this trend. This is attributed to the rise in prevalence of severe aortic stenosis cases coupled with the increase in population of inoperable patients, and high adoption rate of advanced transcatheter aortic valves. However, Asia-Pacific is estimated to grow at a high CAGR (in terms of value and volume) throughout the analysis period, owing to the presence of ample growth opportunities in terms of unmet medical needs for the treatment of aortic stenosis and increase in awareness about TAVI procedures among physicians.
Access Full Summery @ https://www.alliedmarketresearch.com/tavi-market
